NCT02803437Completed
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Source: ClinicalTrials.gov · Last updated 10 Jul 2025
Brief summary (registry, in English)
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 334 (actual)
- First submitted
- 14 Jun 2016
- Start date
- 21 Jul 2016
- Primary completion date
- 6 Jan 2022
- Lead sponsor
- Bayer
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT02803437
What you commit to
- Study type: Observational
- Participants enrolled: 334
- From 21 Jul 2016 to the primary completion date, 6 Jan 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated Xofigo previously
Other
- Patients participating in an investigational program with interventions outside of routine clinical practice
Who the study is looking for
- Patients suffered from CRPC with bone metastases
- Patients for whom the decision to initiate treatment with Xofigo is made as per physician's routine clinical practice.
- Xofigo treatment naïve
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Multiple Locations | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.